MAPT and Alzheimer disease: Although PET imaging using tracers that bind tau and Aβ are being used in the antemortem diagnosis of AD in both clinical and research settings,69, 70, 71, 72, 73 there are currently no validated radiotracers able to bind TDP‐43 in vivo, and no biofluid assays for TDP‐43 have been validated.